Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Silence Therapeutics ADR Representing 3 Ord Shs SLN

Healthcare Biotechnology
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence... see more

Recent & Breaking News (NDAQ:SLN)

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Business Wire March 5, 2025

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Business Wire February 27, 2025

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Business Wire February 13, 2025

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Business Wire December 9, 2024

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Business Wire November 26, 2024

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Business Wire November 18, 2024

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Business Wire November 14, 2024

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Business Wire November 13, 2024

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Business Wire August 27, 2024

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Business Wire August 15, 2024

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Business Wire June 27, 2024

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Business Wire June 24, 2024

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Business Wire June 20, 2024

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

Business Wire May 30, 2024

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Business Wire May 16, 2024

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Business Wire April 30, 2024

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Business Wire April 29, 2024

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Business Wire April 8, 2024

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Business Wire March 13, 2024

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Business Wire March 13, 2024